(Q37206476)

18 August 2017

1 reference

title

Molecular genetics of lung cancer in people who have never smoked (English)

1 reference

18 August 2017

1 reference

1 reference

Janakiraman Subramanian

series ordinal

1

1 reference

18 August 2017

Ramaswamy Govindan

series ordinal

2

1 reference

18 August 2017

publication date

1 July 2008

1 reference

Lancet Oncology Commission

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

676-682

1 reference

18 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Lung cancer death rates in lifelong nonsmokers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Worldwide epidemiological patterns of lung cancer in nonsmokers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Lung cancer in never smokers--a different disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Diversity of gene expression in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Gene Expression in Lung Adenocarcinomas of Smokers and Nonsmokers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Molecular abnormalities in lung carcinogenesis and their potential clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

The TP53 gene, tobacco exposure, and lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Epigenetics of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Dose effect of smoking on aberrant methylation in non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970174-8

7 January 2021

10.1016/S1470-2045(08)70174-8

Identifiers

DOI

1 reference

18 August 2017

1 reference